Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
NCT01495247 · Novartis Pharmaceuticals · PHASE1/PHASE2 · terminated · last registry update 2020-12-08 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study did not meet Phase Ib primary objective to establish the maximum tolerated dose/recommended dose for Phase II” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-07-27Results posted on the registry: The Methodist Hospital Research Institute, TAK-228 + Tamoxifen (NCT02988986)
- 2020-12-19Results posted on the registry: Calithera Biosciences, Inc, Fulvestrant + Sapanisertib (NCT02756364)
- 2020-04-28Also stopped (withdrawn): Abramson Cancer Center at Penn Medicine, Hydroxychloroquine (HCQ) + Gedatolisib (NCT03400254)
- 2020-03-12Also stopped (withdrawn): Gary Schwartz, TAK-228 + Letrozole (NCT02619669)
- 2020-01-27Results posted on the registry: Calithera Biosciences, Inc, Sapanisertib + Fulvestrant (NCT02049957)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision